Oligopeptides for Immunotherapy Approaches in Ovarian Cancer Treatment

(E-pub Ahead of Print)

Author(s): Darja Kanduc*.

Journal Name: Current Drug Discovery Technologies

Submit Manuscript
Submit Proposal

Abstract:

Anti-ovarian cancer vaccines based on minimal immune determinants uniquely expressed in ovarian cancer biomarkers and absent in the human proteome appear to promise a high level of sensitivity and specificity for early ovarian cancer immunodiagnostics, immunoprevention, and immunotherapy. In this context, the present study analyses three ovarian cancer biomarkers - namely sperm surface protein Sp17, WAP four-disulfide core domain protein 2, and müllerian-inhibiting substance - and describes a methodology for constructing ovarian cancer biomarker-derived oligopeptide constructs that might be useful for developing new diagnostic and immunotherapeutic approaches.

Keywords: sperm surface protein Sp17, WAP four-disulfide core domain protein 2, müllerian-inhibiting substance, human proteome, low-similarity peptides, synthetic oligopeptide constructs, anti-ovarian cancer vaccines

Rights & PermissionsPrintExport Cite as


Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1570163815666180525071740
Price: $95

Article Metrics

PDF: 14